Slide 1: Fourth Quarter 2025 Earnings
Fourth Quarter 2025 Earnings February 2, 2026
Slide 2: Safe Harbor
Safe Harbor This presentation contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial
Slide 3: Key Takeaways
Key Takeaways Innovation Market Performance Introduction of Signals Encouraging signs from Reproductive Health and Xynthetica, an AI Models-as- Pharma, Academic & Gov’t Immunodiagnostics both a-Service platform remains subdued above expectations Collaboration with Lilly Strong Diagnostic trends Stro
Slide 4: 4Q25 Revenue Highlights
4Q25 Revenue Highlights Segments Geographic Product Mix Diagnostics Life Sciences AMERICAS APAC EU Recurring Non-recurring +MSD Flat +HSD $0.8 B Flat Flat $0.8 B +LSD $0.8 B +DD Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on our we
Slide 5: 2025 Revenue Highlights
2025 Revenue Highlights Segments Geographic Product Mix Diagnostics Life Sciences AMERICAS APAC EU Recurring Non-recurring -LSD -LSD +MSD $2.86 B +LSD +LSD $2.86 B +MSD $2.86 B +HSD Reconciliations to the most directly comparable GAAP measure for the non-GAAP terms presented above are provided on ou
Slide 6: 4Q25 Financial Results
4Q25 Financial Results REVENUE ADJUSTED OP MARGIN ADJUSTED EPS FREE CASH FLOW $772M 29.7% $1.70 $162M +6% y/y -60bps y/y 20% y/y $515M FY25 Organic: Adj. Gross Margin: Adj. Tax Rate: FY25 FCF % Adj. NI: +4% | M&A: 0% | FX: +2% 59.2% | -220bps y/y 6.5% 87% Adj. Net Interest & Other: $23M Reconciliati
Slide 7: 2025 Financial Results
2025 Financial Results REVENUE ADJUSTED OP MARGIN ADJUSTED EPS FREE CASH FLOW $2,856M 27.1% $5.06 $515M +4% y/y -120bps y/y +3% y/y FCF % Adj. NI 87% Organic: Adj. Gross Margin: Adj. Tax Rate: +3% | M&A: 0% | FX: +1% 59.8% | -150bps y/y 14.5% Adj. Net Interest & Other: $84M Reconciliations to the mo
Slide 8: Life Sciences
Life Sciences LIFE SCIENCE SOLUTIONS SOFTWARE REVENUE AJUSTED OP MARGINS Flat 0% Organic Growth 35.6% Total: +2% | M&A: 0% | FX: +2% -130bps y/y $382 M • +LSD growth from Pharma/Biotech, -LSD decline from Acad./Gov’t 4Q25 revenue • Flat Life Science Solutions, seasonal improvement but no budget flus
Slide 9: Diagnostics
Diagnostics IMMUNODIAGNOSTICS REPRODUCTIVE REVENUE AJUSTED OP MARGINS HEALTH +7% Organic Growth 23.4% Total: +10% | M&A: 0% | FX: +3% -230 bps y/y +MSD $390 M • +HSD growth ImmunoDX globally driven by strength outside of China +HSD 4Q25 revenue • +MSD growth Reproductive Health driven by strength in
Slide 10: 2026 Financial Guidance
2026 Financial Guidance REVENUE $2.96B - $2.99B Total: 4% to 5% Organic: 2% to 3% FX: +1%, M&A: +0.75% ADJUSTED OP. MARGIN 28.0% ADJUSTED EPS $5.35 - $5.45 Adj. Net interest expense, other: ~$95M Adjusted tax rate: ~18% Average diluted share count: ~112M 10
Slide 11: Revvity.com
Revvity.com